GO:0008073 ornithine decarboxylase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008073 describes the molecular function of binding to and inhibiting ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.
• ODC inhibition reduces polyamine levels, which is critical for controlling cell proliferation, transformation, and tumor growth.
• Natural and synthetic ODC inhibitors include difluoromethylornithine (DFMO), allicin, herbacetin, and antizyme, each with distinct mechanisms.
• ODC inhibitor activity is essential for normal cellular regulation and is implicated in cancer, neuroblastoma, glioblastoma, and other diseases.
• Experimental approaches to study ODC inhibitors include enzyme assays, cell proliferation assays, and CRISPR-based gene editing.
• Targeting ODC inhibitor activity is a promising therapeutic strategy, with DFMO approved for African trypanosomiasis and under investigation for cancer.
Description
Ornithine decarboxylase inhibitor activity (GO:0008073) is a molecular function that directly regulates polyamine biosynthesis by binding to and inhibiting ornithine decarboxylase (ODC). ODC catalyzes the decarboxylation of ornithine to putrescine, the first and rate-limiting step in polyamine synthesis. Polyamines (putrescine, spermidine, and spermine) are essential for cell growth, differentiation, and survival, and their dysregulation is linked to cancer and other diseases. The activity of ODC inhibitors is therefore a key control point in cellular physiology. This article explores the definition, mechanisms, genes, and research methods associated with GO:0008073, based on authoritative QuickGO data and verified PubMed literature.
ornithine decarboxylase inhibitor activity At A Glance
| GO ID | GO:0008073 |
|---|---|
| GO term | ornithine decarboxylase inhibitor activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binds to and inhibits ornithine decarboxylase, reducing polyamine synthesis |
| Major proteins | Antizyme, antizyme inhibitor, and small molecule inhibitors such as DFMO |
| Related diseases | Cancer, neuroblastoma, glioblastoma, trypanosomiasis |
| Research methods | Enzyme assays, CRISPR knockout, overexpression, inhibitor screening |
What Is GO:0008073?
According to the Gene Ontology, ornithine decarboxylase inhibitor activity (GO:0008073) is defined as the function of binding to and stopping, preventing, or reducing the activity of ornithine decarboxylase. This activity is carried out by proteins or small molecules that interact with ODC, leading to decreased polyamine production. It is a molecular function term, distinct from enzyme regulator activity, and is critical for maintaining cellular polyamine homeostasis.
Why Is ornithine decarboxylase inhibitor activity Important in Cell Biology?
ODC inhibitor activity is crucial because it controls the first committed step in polyamine biosynthesis, a pathway essential for cell proliferation and survival. Dysregulated polyamine metabolism is a hallmark of many cancers, and inhibiting ODC has been shown to suppress tumor growth and transformation. Moreover, ODC inhibitors like DFMO are used clinically for African trypanosomiasis and are being explored for cancer therapy. Understanding this activity at the molecular level enables the development of targeted therapies and research tools.
• Regulates polyamine levels, which are essential for cell growth and differentiation.
• Inhibition of ODC activity can block cell transformation and tumorigenesis.
• Provides a therapeutic strategy for cancers such as neuroblastoma and glioblastoma.
• DFMO, a well-known ODC inhibitor, is approved for treating African trypanosomiasis.
• Natural compounds like allicin and herbacetin act as ODC inhibitors with antitumor activity.
• Antizyme is an endogenous protein inhibitor of ODC, highlighting physiological regulation.
• ODC inhibitor activity is a target for drug discovery and development.
• Studying ODC inhibitors helps elucidate polyamine homeostasis and its role in disease.
• CRISPR-based models enable precise dissection of ODC inhibitor function in cells.
• Understanding ODC inhibition can lead to novel combination therapies in oncology.
Molecular Mechanism of ornithine decarboxylase inhibitor activity
Binding to Ornithine Decarboxylase
In simple terms: Inhibitors physically attach to the ODC enzyme to block its action.
Ornithine decarboxylase inhibitor activity involves the direct binding of inhibitor molecules to ODC. This binding can occur at the active site or at allosteric sites, preventing the enzyme from catalyzing the decarboxylation of ornithine. For example, difluoromethylornithine (DFMO) is a suicide inhibitor that covalently modifies the active site, leading to irreversible inhibition. Herbacetin, a flavonoid, acts as an allosteric inhibitor, binding to a site distinct from the active site and inducing conformational changes that reduce ODC activity. Antizyme, a regulatory protein, binds to ODC and targets it for degradation, thereby inhibiting its function.
Inhibition of Catalytic Activity
In simple terms: Once bound, inhibitors stop ODC from converting ornithine to putrescine.
The binding of inhibitors to ODC results in decreased catalytic conversion of ornithine to putrescine. This reduces the pool of polyamines, which are required for DNA stability, translation, and cell cycle progression. Studies have shown that DFMO enantiomers inhibit human ODC with different potencies, highlighting stereochemical specificity. Allicin, a compound from garlic, also inhibits ODC in neuroblastoma cells, leading to reduced polyamine levels and antiproliferative effects. The inhibition can be reversible or irreversible depending on the inhibitor.
Regulation by Antizyme and Antizyme Inhibitor
In simple terms: Cells use proteins like antizyme to naturally control ODC levels.
Antizyme is a key physiological inhibitor of ODC. It binds to ODC, inhibits its activity, and promotes its degradation via the proteasome. Antizyme inhibitor (AZIN) can bind to antizyme and prevent it from inhibiting ODC, thus indirectly increasing ODC activity. This regulatory loop is critical for maintaining polyamine homeostasis. The balance between antizyme and AZIN determines ODC activity and polyamine levels, and its disruption is associated with cancer.
Downstream Effects on Polyamine Metabolism
In simple terms: Blocking ODC lowers polyamines, affecting many cellular processes.
Inhibition of ODC leads to decreased putrescine and subsequently reduced spermidine and spermine levels. This affects numerous cellular processes, including DNA replication, transcription, and translation. Polyamine depletion can induce cell cycle arrest and apoptosis. In cancer cells, ODC inhibition has been shown to suppress proliferation and induce differentiation. The downstream effects are mediated by the reduced availability of polyamines for critical cellular functions.
Key Genes Involved in GO:0008073 ornithine decarboxylase inhibitor activity
The following genes and proteins are directly involved in ornithine decarboxylase inhibitor activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ODC1 | Encodes ornithine decarboxylase, the target of inhibition | Central to polyamine biosynthesis; target for inhibitors |
| AZIN1 | Encodes antizyme inhibitor, which binds antizyme and prevents ODC inhibition | Regulates ODC activity indirectly; implicated in cancer |
| OAZ1 | Encodes antizyme 1, a natural inhibitor of ODC | Key physiological inhibitor; targets ODC for degradation |
| OAZ2 | Encodes antizyme 2, another ODC inhibitor | May have tissue-specific roles in ODC regulation |
| OAZ3 | Encodes antizyme 3, testis-specific ODC inhibitor | Potential role in spermatogenesis |
| AZIN2 | Encodes antizyme inhibitor 2, similar to AZIN1 | May regulate ODC in specific tissues |
| PSME1 | Proteasome activator subunit, involved in antizyme-mediated ODC degradation | Links ODC inhibition to proteasomal degradation |
| PSME2 | Proteasome activator subunit, involved in ODC degradation | Part of the regulatory complex |
| PSMA1 | Proteasome subunit, degrades ODC after antizyme binding | Essential for ODC turnover |
| PSMB1 | Proteasome subunit, involved in ODC degradation | Potential target for modulating ODC levels |
| EIF5A | Translation factor activated by spermidine, downstream of ODC | Links polyamine levels to translation |
| SAT1 | Spermidine/spermine N1-acetyltransferase, catabolizes polyamines | Counteracts ODC activity |
| SMOX | Spermine oxidase, catabolizes spermine | Regulates polyamine pool |
| PAOX | Peroxisomal N1-acetyl-spermine/spermidine oxidase | Polyamine catabolism |
| AMD1 | S-adenosylmethionine decarboxylase, produces decarboxylated SAM for polyamine synthesis | Cooperates with ODC in polyamine biosynthesis |
| SRM | Spermidine synthase, converts putrescine to spermidine | Downstream of ODC |
| SMS | Spermine synthase, converts spermidine to spermine | Downstream of ODC |
| MYC | Oncogene that transcriptionally activates ODC1 | Links ODC to cancer |
How Is ornithine decarboxylase inhibitor activity Regulated?
Ornithine decarboxylase inhibitor activity is regulated at multiple levels. Antizyme (OAZ1) is induced by polyamines and binds to ODC, inhibiting its activity and targeting it for proteasomal degradation. Antizyme inhibitor (AZIN1) can sequester antizyme, thereby preventing ODC inhibition. Additionally, ODC is regulated by transcriptional mechanisms, such as MYC activation, and by translational and post-translational modifications. Small molecule inhibitors like DFMO can irreversibly inhibit ODC, overriding physiological regulation.
ornithine decarboxylase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ODC1 | Cancer, neuroblastoma, glioblastoma | CRISPR knockout in cancer cell lines |
| AZIN1 | Cancer, polyamine homeostasis | Overexpression and knockout models |
| OAZ1 | Cancer, polyamine regulation | Knockout and knock-in models |
| MYC | Cancer, ODC transcriptional activation | CRISPR activation/inhibition |
| EIF5A | Cancer, translation regulation | Point mutation models |
Cancer
ODC inhibitor activity is closely linked to cancer. Elevated ODC and polyamine levels are common in many tumors, and inhibition of ODC suppresses cell transformation and tumor growth. DFMO, an irreversible ODC inhibitor, has shown antitumor activity in neuroblastoma and glioblastoma models. Herbacetin, a natural allosteric inhibitor, also exhibits antitumor effects by reducing polyamine levels. Targeting ODC inhibitor activity is therefore a promising therapeutic strategy in oncology.
Neuroblastoma
In neuroblastoma cells, allicin acts as a potent ODC inhibitor, reducing polyamine levels and inhibiting cell proliferation. This suggests that ODC inhibitor activity could be exploited for neuroblastoma therapy. The study highlights the potential of natural compounds as ODC inhibitors in pediatric cancers.
Glioblastoma
Reprogramming tumor-associated macrophages by ODC inhibitor and immune checkpoint blockade has been explored for glioblastoma photothermal immunotherapy. This approach combines ODC inhibition with immunotherapy to enhance antitumor responses, demonstrating the therapeutic potential of targeting ODC inhibitor activity in glioblastoma.
Parasitic Infections
DFMO, an ODC inhibitor, is used clinically to treat African trypanosomiasis (sleeping sickness) because Trypanosoma brucei relies on ODC for polyamine synthesis. This highlights the broader applicability of ODC inhibitor activity beyond cancer.
From ornithine decarboxylase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ODC inhibition affect tumor growth? | ODC1 knockout cancer cell lines and xenografts |
| What is the role of antizyme in ODC regulation? | OAZ1 overexpression and knockout models |
| Can point mutations in ODC alter inhibitor sensitivity? | CRISPR point mutation knock-in of ODC1 |
| How does antizyme inhibitor affect polyamine levels? | AZIN1 knockout and overexpression |
| What are the downstream effects of ODC inhibition? | Transcriptomics and proteomics in ODC-inhibited cells |
| Can ODC inhibitors synergize with immunotherapy? | Syngeneic tumor models with ODC inhibitor and checkpoint blockade |
How to Study the ornithine decarboxylase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ODC enzyme assay | Inhibition of ODC catalytic activity | Screening and characterizing inhibitors |
| Cell proliferation assay | Effect on cell growth | Evaluating antiproliferative effects |
| Polyamine quantification | Levels of putrescine, spermidine, spermine | Confirming downstream effects |
| Western blot | Protein expression of ODC, antizyme, AZIN | Assessing regulation |
| CRISPR knockout | Loss-of-function of ODC1, OAZ1, AZIN1 | Determining gene function |
| CRISPR knock-in | Introduction of point mutations | Studying inhibitor binding sites |
| RNA-seq | Transcriptional changes upon ODC inhibition | Identifying downstream pathways |
| Proteomics | Protein-level changes | Uncovering ODC interactors |
Enzyme Activity Assays
ODC inhibitor activity can be measured using enzyme assays that quantify the conversion of ornithine to putrescine. Radioactive or fluorescent substrates are commonly used. For example, the inhibition potency of DFMO enantiomers was determined using such assays. These methods are essential for screening and characterizing ODC inhibitors.
Cell Proliferation and Viability Assays
The effect of ODC inhibitors on cell growth is assessed using proliferation assays (e.g., MTT, BrdU) and viability assays. Allicin and herbacetin were shown to inhibit neuroblastoma and cancer cell proliferation, respectively. These assays link ODC inhibitor activity to cellular outcomes.
Polyamine Quantification
Polyamine levels (putrescine, spermidine, spermine) can be quantified using HPLC or mass spectrometry. This measures the downstream impact of ODC inhibition. Studies have used such methods to confirm that ODC inhibitors reduce polyamine pools.
CRISPR-Based Genetic Models
CRISPR/Cas9 can be used to knockout ODC1, OAZ1, or AZIN1 to study their roles in ODC inhibitor activity. Knock-in of point mutations can reveal residues critical for inhibitor binding. Overexpression models can assess the effects of increased ODC or antizyme levels.
How CRISPR Can Be Used to Study GO:0008073 ornithine decarboxylase inhibitor activity
Knockout
CRISPR knockout of ODC1 can eliminate ODC expression, mimicking complete inhibition. This is useful to study the consequences of ODC loss on polyamine levels and cell growth. Knockout of OAZ1 or AZIN1 can reveal their roles in regulating ODC inhibitor activity.
Point Mutation
Point mutations in ODC1 can be introduced to study residues critical for inhibitor binding or catalysis. For example, mutating the active site can render ODC resistant to DFMO, helping to map the binding interface.
Knock-in
Knock-in of tagged ODC1 (e.g., GFP or FLAG) allows for visualization and immunoprecipitation of ODC, facilitating studies of its interactions with inhibitors and regulatory proteins.
Overexpression
Overexpression of ODC1 or AZIN1 can increase polyamine levels and promote cell proliferation, providing a model to test ODC inhibitors. Conversely, overexpression of OAZ1 can inhibit ODC and reduce polyamines.
How EDITGENE Supports ornithine decarboxylase inhibitor activity Research
Researchers studying ornithine decarboxylase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in polyamine regulation, cancer, or drug response. EDITGENE provides comprehensive CRISPR-based services to create precise cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for ornithine decarboxylase inhibitor activity research.
Frequently Asked Questions About ornithine decarboxylase inhibitor activity
What is ornithine decarboxylase inhibitor activity?
It is a molecular function (GO:0008073) where a molecule binds to and inhibits ornithine decarboxylase, reducing polyamine synthesis.
What genes are involved in ornithine decarboxylase inhibitor activity?
Key genes include ODC1 (the target), OAZ1 (antizyme), and AZIN1 (antizyme inhibitor).
How does DFMO inhibit ornithine decarboxylase?
DFMO is a suicide inhibitor that covalently modifies the ODC active site, leading to irreversible inhibition.
What diseases are associated with ODC inhibitor activity?
Cancer, neuroblastoma, glioblastoma, and African trypanosomiasis are linked to ODC inhibition.
Can natural compounds inhibit ODC?
Yes, allicin from garlic and herbacetin are natural ODC inhibitors with antitumor activity.
How is ODC inhibitor activity measured?
It is measured using enzyme assays that quantify the conversion of ornithine to putrescine, often with radioactive or fluorescent substrates.
What is the role of antizyme in ODC inhibition?
Antizyme binds to ODC, inhibits its activity, and targets it for proteasomal degradation.
What is antizyme inhibitor?
Antizyme inhibitor (AZIN) binds to antizyme and prevents it from inhibiting ODC, thus increasing ODC activity.
Can CRISPR be used to study ODC inhibitor activity?
Yes, CRISPR knockout, knock-in, and overexpression models can dissect the roles of ODC1, OAZ1, and AZIN1.
Why is ODC inhibition important in cancer?
ODC inhibition reduces polyamines, which are essential for tumor cell proliferation, and can suppress tumor growth.
Conclusion
Ornithine decarboxylase inhibitor activity (GO:0008073) is a critical molecular function that regulates polyamine biosynthesis by inhibiting ODC. Its dysregulation is implicated in cancer and other diseases, making it a prime therapeutic target. Understanding the mechanisms, genes, and research methods associated with this activity is essential for developing novel inhibitors and CRISPR-based models. EDITGENE provides comprehensive services to support such research, from knockout to overexpression and screening.
References
- 1. Zhang X et al.. 2025. Reprogramming Tumor-Associated Macrophage by Ornithine Decarboxylase Inhibitor and Immune Checkpoint for Orthotopic Glioblastoma Photothermal Immunotherapy.. ACS Appl Mater Interfaces 17(24):35155-35167 PMID: 40461940
- 2. Schultz CR et al.. 2020. Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.. J Nat Prod 83(8):2518-2527 PMID: 32786875
- 3. Qu N et al.. 2003. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.. Biochem J 375(Pt 2):465-70 PMID: 12859253
- 4. Kim DJ et al.. 2016. Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.. Cancer Res 76(5):1146-1157 PMID: 26676750
- 5. Auvinen M et al.. 1992. Ornithine decarboxylase activity is critical for cell transformation.. Nature 360(6402):355-8 PMID: 1280331
- 6. Kitani T et al.. 1989. Purification and characterization of antizyme inhibitor of ornithine decarboxylase from rat liver.. Biochim Biophys Acta 991(1):44-9 PMID: 2713421
- 7. Somani RR et al.. 2018. Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases.. Mini Rev Med Chem 18(12):1008-1021 PMID: 28971766
- 8. Schultz CR et al.. 2025. Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors.. J Med Chem 68(5):5760-5773 PMID: 40035393
